Evidence map›Paper›PMID 37893115›Full record

ArticleBiomedicines2023

Methoxyhispolon Methyl Ether, a Hispolon Analog, Thwarts the SRC/STAT3/BCL-2 Axis to Provoke Human Triple-Negative Breast Cancer Cell Apoptosis In Vitro.

Chih-Pin Liao, Ya-Chu Hsieh, Chien-Hsing Lu, Wen-Chi Dai, Wei-Ting Yang, Kur-Ta Cheng, Modukuri V Ramani, Gottumukkala V Subbaraju, Chia-Che Chang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Chih-Pin LiaoDivision of General Surgery, Department of Surgery, Kuang Tien General Hospital, Taichung 433401, Taiwan.
Ya-Chu HsiehDoctoral Program in Tissue Engineering and Regenerative Medicine, National Chung Hsing University, Taichung 402202, Taiwan.ORCID 0009-0009-8815-5966
Chien-Hsing LuDoctoral Program in Translational Medicine, National Chung Hsing University, Taichung 402202, Taiwan.ORCID 0000-0001-7860-4320
Wen-Chi DaiDoctoral Program in Biotechnology Industrial Innovation and Management, National Chung Hsing University, Taichung 402202, Taiwan.
Wei-Ting YangDepartment of Life Sciences, National Chung Hsing University, Taichung 402202, Taiwan.
Kur-Ta ChengDepartment of Biochemistry and Molecular Cell Biology, Taipei Medical University, Taipei 110301, Taiwan.
Modukuri V RamaniDepartment of Organic Chemistry, Andhra University, Visakhapatnam 530003, India.
Gottumukkala V SubbarajuDepartment of Organic Chemistry, Andhra University, Visakhapatnam 530003, India.
Chia-Che ChangDoctoral Program in Translational Medicine, National Chung Hsing University, Taichung 402202, Taiwan.ORCID 0000-0003-3509-3713
National Chung Hsing University · TWAndhra University · INAsia University · TWTaipei Medical University · TW

Funding

The iEGG and Animal Biotechnology Center from the Feature Areas Research Center Program, within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan MOE-112-S-0023-A
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with few treatment options. A promising TNBC treatment approach is targeting the oncogenic signaling pathways pivotal to TNBC initiation and progression. Deregulated activation of signal transducer and activator of transcription 3 (STAT3) is fundamental to driving TNBC malignant transformation, highlighting STAT3 as a promising TNBC therapeutic target. Methoxyhispolon Methyl Ether (MHME) is an analog of Hispolon, an anti-cancer polyphenol found in the medicinal mushroom

Indexed as

apoptosisBCL-2hispolonmethoxyhispolon methyl etherSRCSTAT3triple-negative breast cancer

Identifiers

PMID37893115
PMCPMC10604664
OpenAlexW4387476951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.